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Purpose of Review
This is a comprehensive review of the most recent literature on glossopharyngeal
neuralgia (GPN), a relatively rare form of neuropathic facial pain. It covers the
epidemiology, risk factors, pathophysiology, and differential diagnosis given that
glossopharyngeal neuralgia can often be confused with other facial pain syndromes.
Finally, we extensively review recent findings regarding medical or conservative
measures, minimally invasive, and surgical options for potentially treating and managing
glossopharyngeal neuralgia.

Recent Findings
An in-depth analysis of the recent literature indicates that glossopharyngeal neuralgia is
not only rare but its etiology and pathophysiology are complex and are often secondary to
other disease processes. Regardless, current management options are shown to be
effective in controlling pain. Conservatively, first-line management of GPN is
carbamazepine, but gabapentin and eslicarbazepine acetate are suitable alternatives. In
terms of current minimally invasive pain management techniques, pulsed radiofrequency
ablation, nerve blocks, or percutaneous radiofrequency thermocoagulation are effective.
Finally, surgical management involves microvascular decompression and rhizotomy.

Summary
While there are currently many viable options for addressing glossopharyngeal neuralgia
pain ranging from conservative to surgical management, the complex nature of GPN
etiology, pathophysiology, and involved anatomical structures prompts further research
for more effective ways to treat the disease.

INTRODUCTION
Neuropathic facial pain is produced by a lesion or dysfunction in the central or peripheral somatosensory nervous
system that causes significant impairment to an individual’s quality of life and may result in medical, dental, social,
and psychological burdens.1,2 Local trauma or systemic disorders can trigger this pain as it causes disruption of structures along the central nervous system neuroaxis to struc-

a

Corresponding author:
Juyeon Kakazu, MS
Georgetown University School of Medicine
3900 Reservoir Road NW
Washington, D.C., 20007
Phone: (808) 351-2379
jck107@georgetown.edu

tures in the periphery. Neuropathic pain can be divided
into two broad categories: episodic and continuous pain.
Episodic neuropathies are defined as paroxysmal, shortlasting, stabbing, or shock-like pain as seen in trigeminal
and glossopharyngeal neuralgias. Continuous pain is characterized to be a more constant, dull, achy pain. Examples
of continuous pain include peripheral neuritis, persistent
idiopathic facial pain, and post-herpetic neuralgia.1,3
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Glossopharyngeal neuralgia (GPN), unlike its counterpart, trigeminal neuralgia, is an extremely rare pain syndrome. It produces an electric, shooting pain in the sensory
distribution of the auricular and pharyngeal branches of
the glossopharyngeal (IX) and vagus (X) cranial nerves. The
area of involvement includes the ear, base of tongue, throat,
tonsillar fossa, and angle of the jaw. GPN is characterized as
a brief, unilateral pain with abrupt onset and cessation that
can be easily triggered by simple actions such as talking,
swallowing, yawning, and coughing.4 Touching the external
auditory canal and the side of the neck can also elicit pain.
An episode can last anywhere from 2 seconds to 2 minutes
and can occur up to 200 times per day.5 Although GPN typically occurs unilaterally, some individuals have described
bilateral involvement.6 Occasionally, GPN has been associated with episodes of syncope, bradycardia, and seizures.
When these symptoms occur, GPN is renamed vagoglossopharyngeal neuralgia (VGPN) due to its accompanying involvement of the vagus nerve.4
Appreciating the anatomy helps to better understand the
symptoms and triggers of GPN. The glossopharyngeal nerve
exits the brainstem from the medulla and goes through the
jugular foramen to exit the skull.7 There are five branches of
the glossopharyngeal nerve. The tympanic branch not only
delivers parasympathetic innervation to the parotid gland,
but also provides sensation to the medial surface of the
tympanic membrane, the mucosa of the middle ear, and the
upper eustachian tube.8 The stylopharyngeus branch innervates the stylopharyngeus muscle to allow for elevation of
the pharynx during talking and swallowing.7,8 The pharyngeal branch delivers sensory innervation to the pharynx.
Together with the vagus nerve, the carotid sinus branch
provides parasympathetic innervation from the chemoreceptor in the carotid body and baroreceptors in the carotid
sinus which may play a role in the syncopal episodes that
occur in VPGN.4,7 The glossopharyngeal nerve gives off its
terminal tonsillar and lingual branches which carry somatosensory and taste from the posterior one-third of the
tongue.9
Glossopharyngeal neuralgia is diagnosed clinically, but
because of its location, clinical features, and rarity, diagnosis is often difficult. It can overlap with other cranial nerve
etiologies leading to misdiagnosis. GPN is often misdiagnosed as trigeminal neuralgia (TN) as they share similar
clinical features and affect areas that are next to each
other.7 Typically, GPN produces pain on the left side of the
body, whereas trigeminal neuralgia affects the right side.2
Bilateral pain and associations with multiple sclerosis are
more common in TN. It is important to note that individuals
may suffer from both GPN and TN as the glossopharyngeal
nerve can connect with the mandibular division of the
trigeminal nerve. Although there may be difficulties with
diagnosis, management of GPN is essentially identical to
that of TN.7

ature as well as clinical trial studies to reflect the validity of
the review. Older articles were included as well to refer to
previous background information.
The PubMed and Google Scholar keywords searched were
as follows: glossopharyngeal neuralgia, carbamazepine,
pulsed radiofrequency ablation, nerve blocks, or percutaneous radiofrequency thermocoagulation.

METHODS

Clinically, glossopharyngeal neuralgia presents with acute,
abrupt onset of repeated episodes of severe, sharp, stabbing
unilateral pain in the areas of the sensory distribution of
the glossopharyngeal nerve, along with a branch of sensory
vagus nerves. These areas include the mastoid, the back of
the throat, posterior 1/3 of the tongue, back of the nose,

We conducted literature searches using PubMed and Google
Scholar between October 2020 through March 2021. Articles were chosen based on relevance to glossopharyngeal
neuralgia and treatment options. We selected primary liter-

EPIDEMIOLOGY
Glossopharyngeal neuralgia is a rare condition that occurs
far less than other cranial neuralgias, such as trigeminal
neuralgia. It accounts for only 0.2-1.3% of all cranial neuralgias, affecting 0.2-0.4 per 100,000 people per year, with
a solidified incidence rate of 0.7 per 100,000 people. The
incidence of glossopharyngeal neuralgia increases with increasing age, and most commonly affects adults older than
50 years of age. In a retrospective review of the data on
glossopharyngeal neuralgia published in 1981, 57% of the
217 cases studied occurred in patients over the age of 50,
and 43% affected ages 18-50. Glossopharyngeal neuralgia
occurs equally in both males and females, with no gender
predilection, but it is, however, typically observed more often on the left side in females. Spontaneous remission of
pain episodes was reported by 74% of patients in the same
study previously mentioned, and only 17% had constant
pain without relief. 88% of patients reported unilateral
pain, while the other 12% had bilateral pain in the sensory
distribution of the glossopharyngeal nerve.10

RISK FACTORS AND COMORBIDITIES
Glossopharyngeal neuralgia, like trigeminal neuralgia, typically manifests in individuals who are 50 years old and
older. Manifestations of GPN increase with age; therefore,
age is the primary risk factor for developing GPN. Although
there is a higher incidence in females that are affected by
pain in the head and neck regions, as well as a higher incidence of females exhibiting orofacial pain, there appears to
be no gender preference in GPN. Therefore, both men and
women are equally affected in GPN.11
In some cases of GPN, patients are found to have cardiovascular or neurological symptoms such as asystole, bradycardia, hypotension, syncope, seizures, or even cardiac arrest. These symptoms result from overlapping connections
with the vagus nerve. In even rarer circumstances, patients
may develop these signs in the absence of the classic pain
symptoms of GPN, making diagnosis even more of a challenge.7 Other rare comorbidities are tinnitus, vertigo, involuntary movements, and neurovegetative phenomena such
as tearing, sweating, salivation, and unilateral mydriasis.12

CLINICAL PRESENTATION AND DIAGNOSIS

Health Psychology Research

2

Glossopharyngeal Neuralgia: Epidemiology, Risk factors, Pathophysiology, Differential diagnosis, and Treatment Options

Eustachian tube and middle ear, tonsils, and voice box. Patients may or may not present with coughing and hoarseness and can have difficulty speaking and swallowing. The
pain typically begins at the back of the tongue or throat and
radiates to the back of the jaw or ear. Rarely, glossopharyngeal neuralgia can cause bradycardia, hypotension, systole,
or even asystole. The longevity of these painful episodes
ranges from seconds to minutes, and they may occur many
times throughout the day or night. Triggers of pain episodes
include, but are not limited to, tinnitus, sudden movement
of the head, touching the periodontium, touching the external surface of the ear, coughing, sneezing, swallowing, talking, laughing, or chewing.13
Glossopharyngeal neuralgia is typically a clinical diagnosis after presenting with the symptoms listed above. The
diagnostic test for glossopharyngeal neuralgia involves
touching a cotton swab to the back of the throat, which elicits severe pain that is then relieved with the application of
a local anesthetic such as lidocaine or bupivacaine. After
the diagnosis has been made, the underlying cause of pain
is determined with a complete history of trauma, radiotherapy, previous surgery to the oral and maxillofacial area,
lab tests including CBC, CMP, erythrocyte sedimentation
rate, and antinuclear antibodies, and finally imaging such
as CT scan, MRI, X-Ray, or MR angiogram. The MR angiogram can help to clarify whether vascular compression is
the cause by locating the posterior inferior cerebellar artery
because it loops up and may compress the supraciliary fossette. If, however, the anterior inferior cerebellar artery is
compressed, surgery is needed to formally diagnose glossopharyngeal neuralgia. Finally, a radiograph will diagnose
glossopharyngeal neuralgia if it is caused by Eagle’s Syndrome.2

DIFFERENTIAL DIAGNOSIS
There are numerous diagnoses that contribute to the differential when a patient comes in with acute onset, severe,
sharp facial pain, such as glossopharyngeal neuralgia. The
list is extensive, and some of the diagnoses that are on the
differential will be discussed below. A comprehensive history with a thorough physical exam can often narrow the
differential to make a diagnosis, but some type of imaging
is frequently required to confirm the suspicion.
TRIGEMINAL NEURALGIA

Trigeminal neuralgia is characterized by sudden onset, unilateral, electric shock-like pain in the distribution of the
second or third branch of the trigeminal nerve. The pain is
episodic and terminates as quickly as it comes on. It is one
of the most common cranial nerve neuralgias, typically affecting elderly females, with an incidence of 4.3 per 100,000
people in the United States. Because it is much more common, glossopharyngeal neuralgia is often misdiagnosed as
trigeminal neuralgia. A comprehensive history and physical
can aid in proper diagnosis.2

SUPRAORBITAL NEURALGIA

Supraorbital neuralgia is a subtype of trigeminal neuralgia
that involves the supraorbital branch. It is a rare disorder
that typically presents with the following triad: forehead
pain that does not radiate, tenderness over the supraorbital
nerve when palpated, and relief of symptoms with nerve
blockade. Any type of facial pain can fall on the list of
differential diagnoses for glossopharyngeal neuralgia, however, the pain associated with supraorbital neuralgia is different in character from which glossopharyngeal neuralgia
presents. Patients with supraorbital neuralgia typically
have sensory dysfunction and the hallmark is pain that is
localized inside or just above the eyebrow.14
SUPERIOR LARYNGEAL NEURALGIA

Superior laryngeal neuralgia can be triggered by talking,
swallowing, coughing, and yawning, and may also be associated with hoarseness and cough, just like glossopharyngeal neuralgia. For this reason, it is on the list of differential diagnoses. Upon palpation of the superior laryngeal
nerve at the location of entrance into the larynx, pain may
be evoked. A physical exam in the clinic can help to differentiate between the pain associated with glossopharyngeal
neuralgia versus the pain associated with superior laryngeal
neuralgia.15
NERVUS INTERMEDIUS NEURALGIA

Nervus intermedius neuralgia is a rare disorder, and like
glossopharyngeal neuralgia, presents with unilateral electric shock-like, stabbing pain that occurs intermittently. It
differs from glossopharyngeal neuralgia, however, in that
the pain is located deep in the ear. This pain may be associated with lacrimation, salivation, or taste disorders. It
is less common for glossopharyngeal neuralgia to present
with shock-like pain deep in the ear, so a comprehensive
history and physical exam can help to narrow the differential.16
NASOCILIARY NEURALGIA

Nasociliary neuralgia, otherwise known as Charlin’s syndrome, nasal nerve syndrome, and nasal ciliary nerve syndrome, presents as an extremely sharp pain in the nasal and
paranasal areas. This pain is typically evoked by palpation
of the lateral aspect of the nostril. This neuralgia is rare,
and the pain primarily radiates to the eyebrow eye, nose, or
jaw. Some associated symptoms are tearing of the eyes, conjunctivitis, congestion, sneezing, and erythema on the forehead. Nasociliary neuralgia still presents with facial pain,
causing it to be on the differential, however, it affects different parts of the face than a typical glossopharyngeal neuralgia.17
OCCIPITAL NEURALGIA

Occipital neuralgia also presents with paroxysmal or shooting/stabbing pain, which also has a deep, aching pain between episodes. Pain can be triggered by palpation of the
occipital nerve, and local anesthesia can result in the reso-
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lution of symptoms. Associated symptoms of occipital neuralgia include visual impairment, ocular pain, tinnitus,
dizziness, and nausea, and because of this, misdiagnoses often occur.16
EAGLE’S SYNDROME

Eagle’s syndrome presents very similarly to glossopharyngeal neuralgia. It occurs when an elongated styloid process
impinges on branches and fibers of the glossopharyngeal
nerve, causing the same symptoms. Imaging is required to
differentiate between primary glossopharyngeal neuralgia
and glossopharyngeal neuralgia symptoms due to an elongated styloid.8
TEMPORAL ARTERITIS

Giant cell temporal arteritis presents with headache, painless vision loss, jaw claudication, and fever. There will be
some temporal artery tenderness to palpation, and the
headache may occur for 2-3 months at a time. This is lower
on the differential list for glossopharyngeal neuralgia due
to the character of pain that is associated with glossopharyngeal neuralgia and how much it differs from this type of
pain, but nonetheless, still needs to be considered in a patient who presents with facial pain. To formally diagnose
temporal arteritis, an ESR should be obtained.18
JACOBSON’S NEURALGIA

Glossopharyngeal neuralgia can present with only sensory
loss at the ear. This is known as the otic form of glossopharyngeal neuralgia, and it is often confused with Jacobson’s
neuralgia. Jacobson’s neuralgia is neuralgia of the tympanic
branch of the glossopharyngeal nerve. It presents very similarly to glossopharyngeal neuralgia, however, will require
imaging to confirm if there is a mass or other anatomical
anomaly that could be causing compression of Jacobson’s
nerve.10
MYOFASCIAL PAIN DYSFUNCTION SYNDROME

Myofascial pain dysfunction syndrome is a psychophysiological disease associated with the muscles of mastication.
It presents as an aching, dull, radiating pain that worsens
with jaw movement. It has a different type of pain than
glossopharyngeal neuralgia, and while it may be lower on
the differential, it still falls on the list due to the facial pain
that occurs with this syndrome.
CLUSTER HEADACHE

Cluster headache may be the lowest on the list of differentials but is still important to mention. Like glossopharyngeal neuralgia, cluster headaches also occur more commonly in women, and present with unilateral facial pain,
but have associated symptoms such as Horner syndrome,
conjunctival injection, and epiphora. The attacks are longer
than glossopharyngeal neuralgia at 15-180 minutes, rather
than seconds to minutes, and attacks occur without any
type of stimulation.19

PATHOPHYSIOLOGY
The majority of cases of glossopharyngeal neuralgia are idiopathic in which no identifiable lesion can be discovered.20
Idiopathic causes may be a result of vascular decompression
or central pontine dysfunction.2 One possible explanation
for vascular compression of the glossopharyngeal nerve is
the posterior inferior cerebellar artery (PICA) compressing
the nerve at the level of the root entry zone, as it leaves
from the medulla and through the jugular foramen.21 Demyelination and axon-degeneration of the glossopharyngeal and vagal cranial nerves may be other idiopathic causes
of GPN.7
Although less commonly attributed to GPN, some individuals may get this pain attacks secondary to other causes.
Secondary glossopharyngeal neuralgia may be related to
malignancies or lesions compressing the glossopharyngeal
nerve. Tumors residing within the cerebellopontine angle
(e.g., schwannomas) compress the glossopharyngeal nerve
as it exits the skull. Other significant tumors that may cause
compression of the nerve include carcinoma of the laryngeal and nasopharyngeal tumors, cranial base tumors,
oropharynx tumors, and tongue tumors.7 Invasion of such
tumors may result in engulfment or displacement of the
glossopharyngeal nerve leading to worsening of symptoms.8 Post-radiation treatment may also lead to the development of GPN. In addition, infections such as tonsillitis,
pharyngitis, arachnoiditis, parapharyngeal abscess, and tuberculosis may contribute to the pain syndrome. Complications of certain surgical produce (e.g. post-tonsillectomy,
post-neck dissection, and post-craniotomy) may result in
disturbances of the glossopharyngeal nerve.2 Certain individuals with syndromes like Eagle’s syndrome (elongated
styloid process), Paget’s syndrome, and Sjogren’s syndrome
may additionally present with GPN.7 In particular, bilateral Eagle syndrome was described to be the cause of bilateral GPN in a documented case report.22 It is theorized
that elongation of the styloid process may irritate the glossopharyngeal nerve as it travels medially to the styloid
process in the neck.23 Additional secondary causes include
vascular malformations, direct carotid puncture, choroid
plexus overgrowth, dental extractions, carotid aneurysms,
and occipital cervical malformations.2,7 There are several
etiologies of GPN; thus, it is important to obtain an extensive imaging workup to adequately rule out other pathological processes.

TREATMENT/MANAGEMENT
Treatment of GPN should involve multiple fields of medicine because there are significant differential diagnoses as
mentioned above, such as Trigeminal Neuralgia, Temporal
arteritis, Jacobson’s neuralgia, superior laryngeal neuralgia,
and myofascial pain dysfunction syndrome. While the medical management of these disorders might be similar, the
surgical approaches after failed conservative treatment are
vastly different and must be differentiated.24 Treatment for
this disease can be broken down into three distinct categories that can be initiated in any order based on the severity of symptoms but most commonly follow one. Treatment
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usually starts with a highly conservative or pharmacological
approach. If that is ineffective, minimally invasive treatment is sought out and then proceeds to surgery as a last
resort. These treatments will be discussed as follows.
MEDICAL/CONSERVATIVE MANAGEMENT

One of the first studies performed by Rushton et al in 1981
showed that an anesthetic can be applied locally at the level
of the oropharynx which can be both diagnostic and therapeutic for GPN. In the past, medical cocaine was used in addition to the anesthetic, and GPN was diagnosed if the pain
was relieved. While this is only a short relief of the pain, it
is an option for those with acute symptoms who desire immediate relief. A positive relief of symptoms from the local
anesthetic also indicates a good candidate for future surgical intervention if medical management does not work.
This study also showed that carbamazepine is favored over
phenytoin by patients for the relief of GPN symptoms.25
Pharmacologic treatment for GPN is very similar to that of
trigeminal neuralgia (TN) due to their similar but not widely
understood pathophysiology, with both showing relief with
anticonvulsants with sodium channel blocking mechanisms.26 Due to the similarity and lack of studies specifically targeting GPN, studies on TN treatments will be briefly
discussed. In a study of rats, carbamazepine was shown to
have the most significant reduction in neuralgia-like pain
when compared with other similar drugs such as baclofen,
clomipramine, and morphine.27 In a case study of a
48-year-old woman with GPN, it was shown that a twomonth trial of gabapentin therapy effectively halted her
symptoms for four years, with no side effects to the medication.28 One group of researchers performed a systematic
review to try and determine whether eslicarbazepine acetate (a member of the dibenzoazepine family) would be
a suitable alternative for the treatment of neuralgias for
those that could not tolerate the first-line treatments such
as carbamazepine. One case study they reviewed showed
that a woman with TN (bilateral from multiple sclerosis)
was able to control her pain with carbamazepine. Unfortunately, she was having significant side effects (symptomatic hyponatremia) that caused her to discontinue the
drug. She was, however, able to control the pain with no
side effects using eslicarbazepine acetate (400 mg) after a
trial of multiple different drugs.29 Another study retrospectively looked at patients with neuralgia-type pain (5 with
TN, 3 with painful diabetic neuropathy, and 2 with postherpetic neuralgia) and showed that patients have a 50% decrease in pain based on a visual analog scale (VAS) after
treatment with an average dose of 800 mg per day of eslicarbazepine.30 Although a few studies showed promising
results, the review article concluded that most of the studies did not have a control group and did not have a large
enough sample size to endorse the use of eslicarbazepine
as a good alternative for carbamazepine in the treatment of
neuralgia pain.31 Another case study of a 78-year-old man
with symptoms of glossopharyngeal neuralgia for 2 years
concluded with his symptoms being treated with 1800 mg
of gabapentin. They tried to use carbamazepine and oxcarbazepine to control the pain but were unsuccessful.32 Although other medications have been shown to work, the

first-line medical treatment continues to be carbamazepine
or oxcarbazepine, with medication side effects being the
main cause of discontinuation, even though patients are
having relief of pain.33 In addition to these pharmacologic
and conservative mechanisms of treatment, additional
therapies such as physical and psychological therapy, and
compressing both hot and cold have shown differing successes, but can be beneficial to some patients.34 If medical
and conservative treatment fails, minimally invasive techniques are an option.
MINIMALLY-INVASIVE OPTIONS

One option for minimally invasive treatment for those not
responding to pharmacotherapy is pulsed radiofrequency
(PRF). In this technique, under CT guidance, pulses of radiofrequency are directed at the problematic nerve. This
changes how the nerve transmits its electrical signals in a
non-ablative manner to reduce the pain that it may be causing. This has been proven to work with patients with GPN
symptoms but Jia et al (2020) performed the first retrospective study to determine the long-term outcomes. They concluded that over the long term, pulsed radiofrequency is an
efficient and safe treatment option for those afflicted with
GPN.35 Because of the success of pulsed radiofrequency in
reducing the painful symptoms of GPN, some researchers
wanted to see if performing the same minimally invasive
procedure would have a similar outcome in patients with
oropharyngeal carcinoma who were experiencing neuralgia
due to the same glossopharyngeal nerve. The study looked
at 25 patients with oropharyngeal carcinoma and for more
than 3 months, the PRF provided a significant reduction in
pain and improvement in sleep in 23 of the patients (92%).
They concluded that the PRF is a promising method for decreasing pain from GPN that is caused by oropharyngeal
cancer.36
Another minimally invasive technique that can be used
for pain reduction is a nerve block. Liu et al (2019) looked
at 12 patients from their hospital with GPN who received a
nerve block near the styloid process and concluded that it
was a safe, ultrasound-guided treatment that provides a significant reduction in pain for up to 18 months.37 Another
woman with GPN secondary to postherpetic neuralgia experienced several weeks of pain reduction after receiving a
nerve block using 2 mL 0.25% bupivacaine and 10 mg dexamethasone and then two more injections at 2 weeks and 4
months.38
The last minimally invasive technique to be discussed
is percutaneous radiofrequency thermocoagulation (PRT)
which has been used for many years as an effective treatment for pain with neuropathic etiology. Wang et al determined that PRT is a safe and effective option for patients
with GPN unable to be treated conservatively after contacting 71 patients who received the treatment. They determined that pain relief was experienced by 78.8% of participants immediately after the procedure and 43.0% 10 years
after the procedure with little to no complications.39 Another retrospective study reviewing the same CT-guided
PRT treatment looked at 117 cases of GPN who either were
failing long-term relief with medical management or who
had contraindications to surgery. They concluded that bar-
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ring minor side effects to the treatment (such as the larynx
and pharynx numbness, hoarseness, and dysphagia which
went away by 12.9 +/- 5.1 weeks), there was a significant
reduction in pain (using the Barrow Neurological Institute
pain scale) for up to 12 years for some patients, indicating
a safe and effective treatment option.40 After trials of minimally invasive techniques, the last resort, which is oftentimes successful, for GPN treatment is surgery.
SURGICAL OPTIONS

The two main surgical options for treatment of glossopharyngeal neuralgia that is refractory to medical management
or are medically indicated are microvascular decompression
(MVD) and rhizotomy. MVD has been widely used for neuralgia-type pain but until recently the long-term outcomes
for treatment of GPN have not been studied. A group in
Shanghai reviewed over 200 cases and determined that the
pain relief after five years was reported to be “excellent”
in 86.9% of patients that answered.41 Just like any operation, MVD does not come without potential side effects.
One common complication experienced by patients is postoperative delirium. Because of delirium’s serious nature and
potential to cause death, He et al (2019) reviewed over 900
cases of patients with primary cranial nerve neuralgia who
received MVD treatment. They wanted to study the patients
who experienced postoperative delirium to determine the
risk factors so they could preemptively identify those that
might be affected to reduce their chances. They found that
there are multiple risk factors including being an elderly
male, preoperative carbamazepine use, sleep disturbances
postoperatively, and hypertension.42 Using this information, surgeons performing MVD can identify those with the
predominant risk factors and stop the delirium from happening, mitigating the deadly risk. To further identify complications of MVD, another group retrospectively analyzed
patients receiving the treatment to determine complications within 30 days postop. They concluded there was a
20% complication rate with the majority of said complications being able to be treated without using any invasive
methods and not life-threatening. However, they were unable to compare to other literature to understand if 20% is a
success rate or not because at the present, there is no standardization in the literature, which the present investigation hopes to clarify.43
Another surgical treatment option for GPN is rhizotomy
of the glossopharyngeal nerve. Ma et al (2016) retrospectively reviewed 103 cases who either underwent glossopharyngeal rhizotomy alone or had it in combination with a
partial vagus nerve rhizotomy. They determined that while
both are a safe and effective way of reducing associated pain
with long-term pain relief for around 93% of subjects, the
combination with vagus nerve rhizotomy had around a 9
times higher complication rate long-term.44 In some cases,
MVD can be attempted along with rhizotomy to achieve
pain relief from GPN. Rui et al (2019) compared the treatment option of MVD to MVD with rhizotomy of the glossopharyngeal nerve. They found that there was no significant difference in the cure rates. They also found that there
was a higher rate of complications such as a cough associated with drinking and hoarseness with MVD plus rhizo-

tomy. Their study indicates that treatment with the addition of rhizotomy to MVD does not raise the incidence of
cure rates of patients with GPN and actually may increase
the risk of complications.45 One group also wanted to see
if a rhizotomy was needed after/during the MVD in order to
achieve appropriate pain control. They were able to determine that MVD was successful enough on its own with 46
out of 46 patients having immediate postoperative pain relief. They also found that after 1 year, 97.8% of them continued to have excellent pain control.46 All of the present
treatments are summarized in Tables 1-3.

CONCLUSION
Glossopharyngeal neuralgia while rare is a complex pain
syndrome that requires multi-faceted management. Many
different medical specialties are involved in caring for patients who are affected by glossopharyngeal neuralgia.
These specialties include neurology, otolaryngology, interventional pain specialists, and neurosurgery. This review
has extensively outlined the epidemiology, risk factors,
clinical presentation, diagnostic criteria, differential diagnoses, pathophysiology, treatment, and clinical trials of
glossopharyngeal neuralgia. Many other pathologies can
present similarly to glossopharyngeal neuralgia, so definite
diagnostic measures are required to make the formal diagnosis. The management of glossopharyngeal neuralgia
can be medical, minimally invasive, or surgical. Medical
management typically includes carbamazepine or oxcarbazepine. Other neuropathic pain medicines can also be
given if carbamazepine or oxcarbazepine do not adequately
improve pain. Glossopharyngeal neuralgia can also be
treated with interventional pain management techniques,
most commonly in the form of a pulsed radiofrequency ablation, nerve blocks, or percutaneous radiofrequency thermocoagulation. There are two main surgical approaches
that can be taken to treat glossopharyngeal neuralgia: microvascular decompression and rhizotomy. Overall, there is
a variable prognosis of glossopharyngeal neuralgia because
it is largely patient-dependent. Most patients only suffer a
single paroxysmal pain episode, with only 25% of patients
requiring surgery for long-term relief and the rest being
treated with medical management. Bilateral pain, multiple severe pain episodes, or unremitting pain are indicators
of poor prognosis.10 Further research is warranted because
glossopharyngeal neuralgia is such a rare disease process,
and more forms of management should be investigated in
the future.
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Table 1. Medical management of glossopharyngeal neuralgia
Author
(Year)

Groups Studied and Intervention

Results and Findings

Conclusions

Rushton
et al.
(1981)25

217 adults diagnosed with glossopharyngeal
neuralgia were managed medically. If treatment
was unsuccessful, surgery was performed for
potential relief of symptoms

18 patients took phenytoin,
with only 2 having enough
relief to avoid surgery
20 patients took
carbamazepine alone, with
only 4 having enough relief to
avoid surgery
129 patients had surgical
treatment: 110 patients had
relief of pain

Carbamazepine is the
favored medication for
medical treatment
Surgery is an effective
option for treatment
of GN

Deseure
et al.
(2017)27

72 rats with infraorbital nerve chronic
constriction injury (a model for trigeminal
neuralgia) were treated with a continuous 1 week
infusion of either 30 mg/day of carbamazepine,
1.06 mg/day baclofen, 4.18 mg/day clomipramine,
and 5 mg/day morphine and observed on
spontaneous or evoked pain behavior

Face grooming (a measure of
pain associated with trigeminal
neuralgia) was shown to be
reduced in those receiving
carbamazepine and baclofen.
Clomipramine and morphine
treated showed no significant
reduction in face grooming
All drugs tested exhibited
antiallodynic effects

Carbamazepine
exhibited the
strongest effects in
reducing neuralgia-like
pain
This can confirm the
use of carbamazepine
as a first line
pharmacologic
treatment for
glossopharyngeal
neuralgia.

Moretti
et al.
(2002)28

Case Study of a 48 year old woman with GN
followed for four years with various medical
treatments

After a trial of Carbamazepine,
Ketolorac, and a steroid,
Gabapentin was initiated at
400 mg six times daily for 2
months. After stopping the
therapy, patient was
asymptomatic for 4 years

Gabapentin is a viable
treatment option for
GN therapy

Gaber et
al.
(2013)29

Case Report of a 62 year old female with
refractory TN and multiple sclerosis who had to
discontinue carbamazepine due to symptomatic
hyponatremia

After trials of gabapentin,
amitriptyline, and topiramate
with no significant relief of
pain, 400 mg of eslicarbazepine
per day provide relief of TN
pain with no medication side
effects.

Eslicarbazepine is a
potential option for
those with neuralgia
type pain who cannot
take first-line
medications due to
side effects.

Garcia et
al.
(2014)30

Retrospective observational study on 10 patients
to determine pain reduction from neuropathictype pain with use of eslicarbazepine acetate (5
with TN, 3 with painful diabetic neuropathy, and 2
with post herpetic neuralgia)

An average dose of 800 mg/day
was given to each patient.
Maximum dose was 1,200 mg/
day in one case. After 3
months, there was a reduction
of at least 50% in pain
according to a visual analog
scale (VAS).

Eslicarbazepine is a
potential option for
those with neuralgia
type pain

Simpson
et al.
(2019)47

Case study of 78year old man with GN symptoms
for 2 years. Trials with carbazepine and
oxcarbazine were unsuccessful

The patient’s pain as able to be
controlled with 1800 mg per
day of gabapentin

Gabapentin is a
suitable option for
treatment of GN pain
for those unable to
handle the side effects
of the first-line
treatments
carbamazepine and
oxcarbazine.
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Table 2. Minimally invasive management of glossopharyngeal neuralgia
Author
(Year)

Groups Studied and Intervention

Results and Findings

Conclusions

Jia et al.
(2020)35

A group of 30 patients with idiopathic
GN treated with CT guided
radiofrequency ablation were
retrospectively investigated to
determine the long-term outcomes of
the treatment

Those with satisfactory pain relief:
93.3% at 12 months
89.6% at 24 months
85.3% at 36 months
79.6% at 48 months
73.0% at 60 months
73.0% at 72 months
54.8% at 84 months
54.8% at 108 months
54.8% at 120 months

Pulsed Radiofrequency is
a safe and effective
treatment option for
those with GN that have
failed medical
management.

Bharti et
al.
(2018)36

A group of 25 patients with pain in the
distribution of the glossopharyngeal
nerve underwent fluoroscopy guided
pulsed radiofrequency (PRF) ablation.

Significant reduction in site specific
pain, odynophagia, and ear pain for all
patients. All patients also reported
better sleep, decreased nausea and
vomiting, and lesser opioid
consumption. Pain relief lasted an
average of 5-9 months.

PRF is safe and effective
at reducing pain in
patients with
oropharyngeal carcinoma
causing GN.

Liu et al.
(2019)37

A total of 12 patients from First
People’s Hospital with GN who received
an ultrasound guided nerve block (total
of 48 injections with 0.5% lidocaine and
40 mg methylprednisolone) were
retrospectively analyzed to determine
pain reduction.

Pain relief effective rate (determined
by decrease in VAS score by >2
points):
Discharge – 83.3%
6 months – 83.3%
12 months – 58.3%
18 months – 33.3%

Ultrasound guided nerve
block of the
glossopharyngeal nerve is
a safe and effective
treatment option for
those experiencing GN
who have failed medical
management

Schuster
et al.
(2018)38

A 51-year-old woman diagnosed with
glossopharyngeal shingles who failed
medical management received a
fluoroscopic guided glossopharyngeal
nerve block.

After a nerve block with 2 mL 0.25%
bupivacaine and 10 mg
dexamethasone and then one again at
2 weeks and then 4 months after that,
the patient experienced multiple
weeks of significant pain relief from
the GN.

A glossopharyngeal nerve
block was effective at
reducing pain from GN in
at least one woman with
postherpetic neuralgia.

Wang et
al.
(2016)39

A total of 71 patients with GN were
retrospectively analyzed after receiving
CT guided percutaneous
radiofrequency thermocoagulation
(PRT) for pain reduction.

Pain reduction (determined by
telephone):
Immediate post-op: 78.8%
Those remaining in “excellent” or
“good” pain relief:
73.2% at 1 year
63.0% at 3 years
53.2% at 5 years
43.0% at 10 years

CT guided PRT is a safe
and effective method for
long term pain relief in
those suffering from GN
who have failed medical
management.

Song et
al.
(2019)40

A total of 117 patients with GN were
retrospectively analyzed after receiving
treatment with CT guided PRT.

82.1% of patients had “excellent”
relief of pain immediately following
intervention
Those experiencing “excellent” pain
relief:
75.9% at 1 year
63.0% at 3 years
54.0% at 5 years
44.2% at 10 years
39.3% at 12.5 years
Adverse events due to intervention
that were resolved by 12.9 +/- 5.1
weeks: abnormal sense of taste,
larynx and pharynx numbness,
hoarseness, and dysphagia.

CT guided PRT is a safe
and effective method for
long term pain relief in
those suffering from GN
who have failed medical
management.
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Table 3. Surgical management of glossopharyngeal neuralgia
Author
(Year)

Groups Studied and
Intervention

Results and
Findings

Conclusions

He et al.
(2019)42

A total of 912 patients who
received microvascular
decompression (MVD) for their
primary cranial nerve neuralgias
were retrospectively analyzed
to determine if they had postoperative delirium in order to
determine the risk factors.

Nearly 24% (221)
of the 912
patients
experienced
post-operative
dementia. The
risk factors were
determined to be:
“old age, male sex,
hypertension,
preoperative
carbamazepine
use,
postoperative
sleep
disturbance, and
tension
pneumocephalus”

These risk factors can be used to preemptively stop a
potentially deadly delirium in those affected before
undergoing microvascular decompression for a
cranial nerve neuralgia.

Bartek
et al.
(2016)43

A group of 98 adult patients with
cranial nerve pain who were
treated with MVD were
retrospectively analyzed to
determine complications after
30 days using a standardized
form.

Overall
complication
rate:
20%
Grade I: 14%
Grade II: 5%
Grade III: 1%
(Using Landriel
Ibanez
classification for
neurosurgical
complications)

They concluded there was a 20% complication rate
with the majority of said complications being able to
be treated without using any invasive methods and
not life threatening. However, they were unable to
compare with other literature to know if 20% is a
successful rate or not because as of yet, there is no
standardization in the literature, which this study
hopes to accomplish.

Ma et al.
(2016)44

103 patients with GN were
treated with either
glossopharyngeal rhizotomy
(GPNR) alone or had it in
combination with a partial vagus
nerve rhizotomy (GPNR+VNR)
and retrospectively analyzed

Only 79 of 103
could be
contacted
38 GPNR alone:
Immediate pain
relief: 94.7%
Immediate
complication
rate: 7.9%
Long-term pain
relief: 92.3%
Long-term
complications:
3.8%
65 GPNR+VNR:
Immediate pain
relief: 93.8%
Immediate
complication
rate:4.6%
Long-term pain
relief: 94.3%
Long-term
complications:
35.8%

While both are a safe and effective way of reducing
associated pain with long-term pain relief for around
93% of subjects, the combination with vagus nerve
rhizotomy had around a 9 times higher complication
rate long-term.

Xia et al.
(2017)41

228 patients with GN were
treated with MVD and then
retrospectively analyzed to
determine long-term outcomes

Immediate postop outcome:
89.5% - excellent
5.3% - good
2.6% - fair
2.6% - poor
>5-year followup (107 cases):
86.9% - excellent
5.6% - good
2.8% fair
4.7% - poor

MVD is an effective and safe treatment option for
long-term relief of GN.
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Rui et al.
(2019)45

Patients with GN were
retrospectively analyzed after
treatment with MVD or MVD
plus rhizotomy of the
glossopharyngeal nerve (MVD +
GNR). Twenty-two patients
were treated with MVD alone
and 15 patients were treated
with MVD + GNR.

MVD alone:
19 cases cured
3 cases improved
•

Complications:
◦ 2 hoarseness
(short-term)
and drinking induced cough, 1
CSF leakage, 1
intracranial infection, 1 ipsilateral hearing
loss

No significant difference in the cure rates. Higher rate
of complications such as a cough associated with
drinking and hoarseness with MVD + GNR. Their
study indicates that treatment with the addition of
rhizotomy to MVD does not raise the incidence of
cure rates of patients with GN and actually may
increase the risk of complications.

MVD + GNR:
14 cured
1 improved
•

Complications
◦ 2 permanent
hoarseness, 4
drinking induced cough
(short-term)
and hoarseness,
1 ipsilateral facial paralysis, 1
CSF leakage

No significant
difference was
noted.
Funct et
al.
(2020)46

A total of 46 patients with GN
unable to be treated medically
were treated with MVD. A
retrospective analysis was
performed to determine
whether MVD alone without
rhizotomy was enough to
control their pain.

100% of patients
had immediate
post-operative
pain relief after
MVD alone.
After 1 year, only
one patient had
occasional return
of pain.

Health Psychology Research
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